Harvard College

Other

The General Hospital Corporation

Children's Medical Center Corporation

Louisiana State University and Agricultural & Mechanical College

President and Fellows of Havard College

Siraganian, Reuben

Philip Leder

Andrew Luster

Timothy Andrew Stewart

John G Flanagan

Christoph H Westphal

Marc Elliot Rothenberg

Philip N Benfey

Michael Klagsbrun

Andrew David Luster

Akira Shimizu

Iris Lindberg

Eduardo Garcia

David M Ornitz

Avner Yayon

Benjamin E Rich

Reuben Siraganian

Brian Seed

Dean H Hamer

Tae-Ho Lee

Ben Z Stanger

Emily Kim

Briggs W Morrison

Marian Kaehler

William J Muller

In general, the invention features methods and uses for transposon-mediated gene targeting which greatly enhance the insertion and detection of desired genes in genomic exons by homologous recombination. The invention also features transgenic non-human mammals, and eukaryotic cells, wherein a gene encoding 7B2 protein is modified, as well as nucleic acid vectors capable of undergoing homologous recombination with an endogenous 7B2 gene in a cell. The invention also features transgenic non-human mammals as models of endocrine disorders, as well as methods for diagnosing and treating patients with endocrine disorders.

7B2 knockout transgenic animals as models of endocrine disease

A cDNA sequence encoding the &#x3b1;-subunit of human mast cell IgE surface receptor or an IgE binding fragment thereof.

DNA encoding IgE Receptor &#x3b1;-subunit or fragment thereof

Disclosed is substantially pure eotaxin DNA sequence and eotaxin polypeptide, and methods of using such DNA and polypeptide to direct chemotaxis of eosinophils. Methods are provided for the treatment diseases and disorders such as inflammation and tumorigenesis.

Eotaxin: an eosinophil chemoattractant

Methods and uses for transposon-based gene targeting

Nucleic acid encoding eotaxin

Methods and therapeutic compositions for inhibiting neoplasms by administration of a nucleic acid sequence encoding the IP-10 polypeptide.

Use of the cytokine IP-10 as an anti-tumor agent

Methods and therapeutic compositions for treating neoplasms by administration of the polypeptide IP-10, or a suitable DNA vector encoding the polypeptide IP-10.

Cytokine IP-10 as an anti-tumor agent

A transgenic non-human eukaryotic animal whose germ cells and somatic cells contain an activated oncogene sequence introduced into the animal, or an ancestor of the animal, at an embryonic stage.

Testing method using transgenic mice expressing an oncogene

Disclosed are methods for modulating endothelial cell proliferation. Also, disclosed are methods of detecting compounds which inhibit IP-10 and PF4 binding to a HSPG receptor.

Modulation of endothelial cell proliferation with IP-10

Disclosed is a method of isolating a ligand from a sample, the method including: providing a hybrid molecule including the receptor for the ligand covalently bonded to the first member of a specific binding pair; contacting sample with the hybrid molecule to form an affinity complex between the ligand and the hybrid molecule; and isolating the affinity complex using the second member of the specific binding pair. Also disclosed is a c-kit ligand, nucleic acid encoding such a ligand, and recombinant cells containing such nucleic acid. The c-kit ligand may be used to stimulate hematopoietic cell growth.

Detection and isolation of receptors

A homogeneous population of cells having on average (1) a number of cell surface low-affinity heparin-binding growth factor (HBGF) sites per cell less than 20% of the number of such binding sites found on wild-type CHO-K1 cells (ATCC Accession No. CCL61), and at least three times the number of cell surface high-affinity HBGF receptors per cell found on such CHO-K1 cells; and an assay system utilizing such cells.

System for assaying binding to a heparin-binding growth factor receptor

Disclosed is a method for the culture of higher eukaryotic cells which are dependent for survival on an exogenous factor. The method involves co-culturing the factor-dependent cells with an immortalized eukaryotic cell that has been engineered to secrete the requisite factor. Also disclosed is a cell line of non-stromal cell origin which secretes interleukin-7.

Cell culture system

A novel chloride channel protein found in human breast cancer cells is disclosed. The chloride channel protein, called Mat-8, serves as a useful diagnostic reagent for the detection of breast cancer. The Mat-8 protein and chloride channel proteins generally, are useful therapeutic targets for the treatment of breast cancer.

DNA encoding Mat-8

Disclosed is a protein, designated RIP, which contains a death domain at its carboxy terminus and a kinase domain at its amino terminus. RIP interacts with the Fas/APO-1 intracellular domain and the TNFR1 intracellular domain. When expressed in transformed host cells, recombinant RIP promotes apoptosis. Also disclosed are DNA molecules encoding RIP, anti-RIP antibodies, and screening methods for discovering inhibitors of RIP-dependent apoptosis.

Growing community of inventors

Chestnut Hill, MA, United States of America

Philip Leder